Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of “Moderate Buy” by Brokerages

Plus Therapeutics, Inc. (NASDAQ:PSTV) has been given a consensus rating of “Moderate Buy” by the seven research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $5.60.

A number of research analysts have recently commented on PSTV shares. HC Wainwright reaffirmed a “buy” rating and set a $1.00 price objective (down from $2.00) on shares of Plus Therapeutics in a research note on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Thursday, January 22nd. D. Boral Capital restated a “buy” rating and issued a $3.00 target price on shares of Plus Therapeutics in a report on Thursday, March 19th. Finally, Lake Street Capital assumed coverage on shares of Plus Therapeutics in a research report on Tuesday, February 3rd. They set a “buy” rating and a $2.00 price target for the company.

Plus Therapeutics Trading Down 6.7%

NASDAQ PSTV opened at $0.21 on Tuesday. The business’s 50-day moving average price is $0.27 and its 200 day moving average price is $0.46. Plus Therapeutics has a twelve month low of $0.16 and a twelve month high of $1.22. The company has a market capitalization of $36.81 million, a PE ratio of -0.17 and a beta of 0.78.

Institutional Trading of Plus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in PSTV. Jane Street Group LLC acquired a new position in Plus Therapeutics in the second quarter valued at $41,000. Altium Capital Management LLC purchased a new stake in Plus Therapeutics during the third quarter valued at about $628,000. Scientech Research LLC acquired a new stake in Plus Therapeutics during the third quarter worth about $100,000. Susquehanna International Group LLP acquired a new stake in Plus Therapeutics during the third quarter worth about $46,000. Finally, Geode Capital Management LLC raised its holdings in shares of Plus Therapeutics by 72.5% in the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after purchasing an additional 589,544 shares during the period. 3.28% of the stock is currently owned by institutional investors and hedge funds.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.